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An equivalence testing method is described to assess the safety of regulated products using relevant data
obtained in historical studies with assumedly safe reference products. The method is illustrated using
data from a series of animal feeding studies with genetically modiﬁed and reference maize varieties.
Several criteria for quantifying equivalence are discussed, and study-corrected distribution-wise equiv-
alence is selected as being appropriate for the example case study. An equivalence test is proposed based
on a high probability of declaring equivalence in a simpliﬁed situation, where there is no between-group
variation, where the historical and current studies have the same residual variance, and where the
current study is assumed to have a sample size as set by a regulator. The method makes use of gener-
alized ﬁducial inference methods to integrate uncertainties from both the historical and the current data.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
There are categories of innovative products that are only
allowed on the market after a risk assessment has shown that the
product is safe for human health and the environment. Examples of
regulated products are drugs, pesticides, and, in e.g. Europe,
genetically modiﬁed organisms (EFSA, 2010b, 2011a). The risk
assessment generally involves a comparative trial inwhich the new
product is compared with already established products. Assessing
safety by means of such a comparative trial is fundamentally
different from data analysis in other scientiﬁc ﬁelds. In most other
testing situations the intention is to prove the existence of a dif-
ference or an effect, for example less incidence of a disease or a
higher yield of an agricultural crop. Therefore, following the prin-
ciple that the intention of testing is to prove a hypothesis to be
wrong, in such studies a null hypothesis of no effect is tested
against an alternative hypothesis that there is an effect. However,
statistical hypothesis testing is an asymmetric procedure, and
absence of a signiﬁcant difference cannot be considered as a
statement about the truth of the null hypothesis, or “absence ofn der Voet), paul.goedhart@
(K. Schmidt).
r Ltd. This is an open access articleevidence is not evidence of absence” (Altman and Bland, 1995).
It is thus impossible to prove exact equality using statistical
procedures. Consequently, safety assessment requires the use of
alternative testing procedures, collectively known as equivalence
testing, to demonstrate that an effect is small enough (Schuirmann,
1987; Walker and Nowacki, 2011). Equivalence testing is well
established as the regulatory required procedure in drug testing
(FDA, 2003; EMA, 2010), and has also been proposed in other ﬁelds
(Garrett, 1997; Cosacov et al., 2008; van der Voet et al., 2011; EFSA,
2011a; Fessel and Snedeker, 2011; Beninger et al., 2012).
Equivalence testing raises two questions. First, on which scale
should potential effects be expressed, and second, what is the
threshold, also called acceptance criterion or equivalence limit, for
‘small enough’? For example, in testing the equivalence of drugs,
regulatory authorities prescribe that certain pharmacokinetic pa-
rameters describing the fate of a drug in human subjects should,
expressed as an average, differ less than a factor of 1.25 between the
tested drug and a reference drug (FDA, 2003; EMA, 2010). This
approach is called average equivalence (AE).
The optimal procedure for equivalence testing has been much
debated in several ﬁelds. In drug bioequivalence testing, it has been
proposed to consider the full distribution of measurements rather
than an average. This leads to more reﬁned concepts such as pop-
ulation bioequivalence, related to the prescribability of drugs, andunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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drugs (Midha et al., 1999; Schall and Endrenyi, 2010). In food safety
assessment, the concept of substantial equivalence was introduced
(OECD, 1993; Kuiper et al., 2001), but its use was mostly in a non-
statistical way and linked to a strong limitation in the number of
variables that should be measured. This led to criticism of the
concept (Ho and Steinbrecher, 1998; Millstone et al., 1999),
although the basic concept of statistical equivalence testing based
on an appropriate set of variables was never challenged.
More in general, it is clear that equivalence testing needs prior
speciﬁcation of the set of variables that should be measured, and of
the equivalence criterion to be used. The set of variables to test
should ideally be limited to those that are informative to risk
assessment based on existing data and scientiﬁc information
available. In this paper our focus is on the statistical procedure for
equivalence testing and wewill assume that the set of variables has
already been established. Different classes of criteria have recently
been discussed by Vahl and Kang (2016) in the context of ﬁeld tests
with genetically modiﬁed and reference crops. Of special interest to
us are scaled average equivalence (SAE) and distribution-wise
equivalence (DWE). Equivalence using SAE is assessed by
comparing means over experimental units. Moreover the accep-
tance criterion is not a ﬁxed value, but is scaled to some relevant
measure of variation. In DWE, on the other hand, full distributions
rather than means are compared.
All forms of equivalence testing need external input, in order to
set a ﬁxed equivalence limit (in AE and SAE), to obtain a scaling
factor (in SAE), or to obtain a reference distribution (in DWE). In
principle there are two approaches to obtain such external input.
The ﬁrst approach is that regulators or experts specify appropriate
values. The factor of 1.25 used in drug equivalence testing (FDA,
2003; EMA, 2010) is an example of this approach. However, even
experts often ﬁnd it difﬁcult to specify equivalence limits in this
way. The second approach is to use additional data to generate the
appropriate input.
In this paper we focus on the use of such additional data which
are obtained for products that serve as a reference for the product
to be tested.We distinguish between two cases. In the ﬁrst case, the
reference products have been measured under similar circum-
stances as the test product, so a direct comparison can be made. For
example, in ﬁeld tests, the test and reference varieties of a crop are
often planted in the same experiment, and consequently previous
work focussed on the comparison of a test variety with a population
of reference varieties (van der Voet et al., 2011; Kang and Vahl,
2014; Vahl and Kang, 2016). In the second case, multiple studies
are considered, and we cannot exclude unspeciﬁed differences
between the measurements in different studies.
Here we consider animal feeding studies, in which not many
feed varieties can be investigated in any single study, and theremay
be differences between the studies related to different experi-
mental conditions. Consequently, the basic idea introduced in this
paper is to compare the difference between a test (T) and a control
(C) variety, obtained simultaneously in a current study, to the
typical differences between reference (R) varieties obtained in one
or more historical studies. In other words, the equivalence analysis
is corrected for between-study differences, and the within-study
variation between references R is used to set equivalence limits
for the difference between T and C in the current study. Such an
approach is in line with the traditional comparative approach in
GMO risk assessment that comparison with available data on the
nearest comparator, as well as with similar varieties on the market,
should form the initial part of the assessment procedure (Kok and
Kuiper, 2003). The variation between reference varieties is a pointof departure in data-based approaches to set equivalence limits. In
the simplest SAE approach of Vahl and Kang (2016) the equivalence
limit is some factor times the variance between the reference va-
rieties. Unfortunately, this prevents the ability to obtain useful
equivalence limits when there is no, or very small, observed vari-
ation between the R varieties. In a DWE approach, as we will see,
also the variance within the reference groups contributes to the
total variation, allowing to obtain equivalence limits. Therefore
DWE testing is the preferred approach when little or no variation
between the R varieties is expected, as for example in biochemical
and haematological measurements from animal feeding trials.
Vahl and Kang (2016) derived DWE equivalence limits based on
a limit case where the variation between the reference varieties
was assumed to be much larger than the residual variation. The
statistical properties of this procedure in the opposite case, i.e. for a
situation with little or no reference variation, are unknown. We
propose an alternative strategy based on desired performance of
the test in a simpliﬁed situation with no reference variation. In
short, wewill deﬁne an equivalence limit as the upper (1-b) limit of
the upper (1-a) conﬁdence limit for a statistic that quantiﬁes a
comparison between two reference varieties that in reality have no
difference. This approach guarantees that equivalence can be
declared with probability 1-bwhen there is no difference in reality
in this simpliﬁed situation. It may be noted that power for an
equivalence test is deﬁned differently than for a traditional differ-
ence test. In the latter case it is the probability of detecting a true
non-zero difference, but the power of an equivalence test is deﬁned
here as the probability of concluding equivalence when in reality
there is no difference.
The use of historical data can conceptually be seen as a two-step
approach: ﬁrst equivalence limits are derived from the historical
data, and secondly these limits are employed in the equivalence
test for the current data. Indeed, the use of external ﬁxed values
(such as the factor of 1.25) can also be considered as an instance of
such two-step reasoning. The two-step approach is conceptually
simple, and a straight-forward use of it has been proposed as a
model for GMO safety assessment (EFSA, 2010a; EFSA, 2011b; van
der Voet et al., 2011). However, the price paid for this simplicity
is that the uncertainty in the estimates of the equivalence limits
based on the reference data (step 1) is not accounted for in step 2
(Kang and Vahl, 2014; Vahl and Kang, 2016).
To allow for all uncertainties simultaneously, it is possible to
derive methods that integrate both steps and explicitly deﬁne
criteria which are a function of the model parameters. Among
several statistical procedures, methods of generalized ﬁducial
inference (Weerahandi, 1993; Krishnamoorthy and Mathew, 2002;
Hannig et al., 2006b, 2016; E et al., 2008; Hannig, 2009; Cisewski
and Hannig, 2012) have been found useful for equivalence
(McNally et al., 2003; Hannig et al., 2006a; Kang and Vahl, 2014,
2016; Vahl and Kang, 2016). We will therefore construct and use
such methods.
The main aims of this paper are therefore:
1. To adapt the equivalence criteria to study-corrected testing, i.e.
to base the equivalence test on the difference between a Test
and a Control in the current study, rather than on the difference
between a Test and a set of reference R varieties;
2. To propose a new equivalence criterion where a full distribution
rather than a mean will be compared to a relevant reference
distribution, based on desirable power in a simpliﬁed situation.
3. To illustrate the use of the proposed method with data from ﬁve
animal feeding studies which included both conventional and
genetically modiﬁed feed groups.
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2.1. Data
Five animal feeding studies with GM and conventional maize
have been performed as part of the EU GRACE project (http://www.
grace-fp7.eu). Studies A, B, D and E were 90-day studies, and study
C was a 1-year study (here we consider only the results obtained at
90 days). The data from the studies are available at the CADIMA
website (https://www.cadima.info). These data have been analysed
before as part of the GRACE project (Schmidt et al., 2015a,b, 2016,
2017; Zeljenkova et al., 2014; 2016). Here we only consider the
feed groups containing 33%maize, which was the high dose level in
the GRACE studies.
In studies A-E there were 3, 3, 2, 1 and 1 non-GM (reference)
groups, respectively, including the isogenic (control) varieties of the
GM (test) varieties. All 6 non-GM varieties in studies A and B were
different, whereas in studies C, D and E some of these were used
again. The variability in the reference data after 90 days in all
studies was summarized in Schmidt et al. (2017). Cages were used
as the experimental unit in a completely randomized design. The
group sample size in studies A and B was 8 cages for all groups. In
study C the group sample size was 10 cages (but only 5 for most
measurements), and in studies D and E the group sample size was 5
cages.
The statistical analysis presented here was performed with re-
sults of 13 haematological variables, 15 clinical chemical variables,
the ﬁnal body weight (at week 13) and 11 organweights (relative to
ﬁnal body weight). In addition, the growth rate r was estimated
from the weights W of each individual animal by ﬁtting the
following exponential growth curve against week number t:
W ¼Wfinal 

Wfinal Winitial

rt
All variables were transformed to the natural logarithmic scale
and then averaged to the cage level. Any outliers were identiﬁed
using Grubb's test at the 1% level. For variables in which outlying
observations were identiﬁed, statistical analyses were performed
with outliers included and excluded to check if this made major
differences. Details of the data pre-processing are documented in
Supplement 1. All calculations in this work were performed with
the statistical program Genstat 18 (https://www.vsni.co.uk/softwa
re/genstat/), and should be easily reproducible with other statisti-
cal software such as R or SAS.2.2. Statistical model
The basic structure of the statistical model is similar to the
model used by van der Voet et al. (2011), Kang and Vahl (2014) and
Vahl and Kang (2016). Let yijk be the log-transformed response of
feed i in study j for unit (cage) k. The following linear mixed model
can then be used for the historical studies j ¼ 1…nS with reference
feeds i ¼ 1…nR, and the current study with test feed i ¼ T and
control feed i ¼ C:
yijk¼
8<
:
mRþRiþSjþEijk
mT þFTk
mCþFCk
i¼1…nR
i¼ T
i¼C
j¼1…nS k¼1…nij
k¼1…nT
k¼1…nC
(1)
Parameters mR, mT and mC correspond to the expected means for
the population of reference feeds R, the test feed T and the control
feed C respectively. The random effect Ri denotes deviations from
mR for the reference feeds in the historic studies and is assumed to
follow a normal distributionwith mean zero and variance s2R. Study
effects Sj, in historical studies j¼1…nS, are considered to be ﬁxed.This implies that the random effects Ri represent variation between
reference feeds within studies. The residual random effects Eijk, for
unit k¼1…nij in the historical studies, and Fik, for units k¼1…ni in
the current study with i¼ T;C, are assumed to follow a normal
distribution with mean zero and variances s2E and s
2
F respectively.
The residual variances in the historic and current studies are thus
allowed to be different (see Discussion for alternative possibilities).
For speciﬁc experimental designs this model can be easily extended
with terms for e.g. blocks within studies. Such extensions are not
needed for our illustrative data.
Note that in this model there is no formal link between the
model for the historical studies and the model for the current study
since the two models have no parameters in common. This is the
main difference with the models used by van der Voet et al. (2011),
Kang and Vahl (2014) and Vahl and Kang (2016), because these
were developed for experiments where reference, test and control
feeds are simultaneously compared in the same experiments.
2.2.1. Statistical model for historical data
The ﬁxed study effects Sj in the historical studies are considered
to be nuisance parameters, and consequently ANOVAmean squares
according to Hendersonmethod III can be employed to estimate the
variance parameters s2R and s
2
E (Searle et al., 1992, p. 213). Deﬁne SSS
as the sums of squares due to differences between studies, SSRjS as
the sums of squares due to differences between feeds within
studies, and SSE as the residual sums of squares.
Writing the linear model for the historical data in obvious ma-
trix notation as y ¼ XSaþ XRbþ e, the accompanying degrees of
freedom are given by dfS ¼ r½XS, dfRjS ¼ r½XS XR  r½XS and
dfE ¼ N  r½XS XR, where r½$ is the rank of a matrix and N ¼ SiSjnij
is the total number of units. The sums of squares and degrees of
freedom are easily obtained by ﬁtting the linear model. The mean
squares msE and msRjS, according to Henderson method III for a
two-way crossed mixed model (Searle et al., 1992, p. 213), can then
be used to estimate the variance components, i.e.
bs2E ¼ msE ¼ SSE=dfE and bs2R ¼ ðmsRjS  msEÞ=neff , in which
neff ¼ h7=dfRjS, h7 ¼ N 
P
j
ðP
i
n2ij=NjÞ and Nj ¼
P
i
nij (see Searle
et al., 1992, p. 211). Note that neff can be interpreted as the effec-
tive unit replication; it equals the common sample size when all nij
are the same. The estimate bs2R can become negative in which case
zero will be used as an estimate. The sums of squares SSRjS and SSE
are independent under normality, even in the unbalanced case (as
shown by Searle et al., 1992, p. 73 for a one-way lay-out). Moreover
SSE follows a scaled chi-squared distribution with dfE degrees of
freedom, i.e. SSE  s2E c2dfE . For balanced data, i.e. all reference feeds
are present in every study and the replication nij ¼ n is constant,
SSRjS also follows a scaled chi-squared distribution now with dfRjS
degrees of freedom: SSRjS  ðn s2R þ s2EÞ c2dfRjS . For unbalanced data
with s2R >0 there is no chi-squared distribution associated with
SSRjS. However the distribution of SSRjS can be approximated for
moderately unbalanced data by means of ðneff s2R þ s2EÞ c2dfRjS ; note
that the expectation of the two distributions are equal. The quality
of the approximation for the illustrative dataset is investigated in
Supplement 2.
2.2.2. Statistical model for current data
The current study is conducted to assess equivalence of the test
feed T and the control feed C. Note that C represents a control type
with special status, and is measured in the same study as T. For
example, if T is a feed with a GM variety, C could be a feed with the
near-isogenic variety. The parameter of interest is therefore the
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mated by the difference between the observed means in the cur-
rent study D ¼ yT :  yC:, which is distributed as D  NðD; a2s2F Þ, or
equivalently ðD DÞ=ðasFÞ  Nð0; 1Þ, inwhich a ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1=nT þ 1=nC
p
.
The variance s2F can be estimated by means of the ratio of the sums
of squares SSF and the corresponding degrees of freedom
dfF ¼ nT þ nC  2, and SSF follows a scaled chi-squared distribu-
tion: SSF  s2F c2dfF independently of D.
In summary the data obtained in the historical and current
studies can be summarized by means of the statistics SSRjS; SSE; D
and SSF which are mutually independent and have distributions of
known form.2.3. Equivalence criteria
In Table 1 six equivalence criteria are presented, organised in
three rows representing the type of equivalence (AE, SAE or DWE)
and two columns representing whether the mean mT of the test T is
compared to the mean of the reference feeds mR, or to the mean mC
of the control feed C. All criteria are based on (expected) squared
differences between means (AE and SAE) or observations (DWE).
The basic idea is that the criterion value should be small enough to
be able to conclude equivalence.
We now explain why we use distribution-wise equivalence in
which T is compared to C for our illustrative data. First, the
‘Compare T to C’ criteria are preferred if the R data are mainly or
completely obtained from previous studies and there may be large
between-study differences. Under these circumstances the esti-
mation of ðmT  mRÞ2 will be imprecise because it will include be-
tween study effects. Note that in other types of experiments, such
as ﬁeld trials with several plant genotypes, the ‘Compare T to R’
approach may be feasible and even preferable, especially when T, C
and R groups are simultaneously compared in the same study or
studies. This was in fact employed by Vahl and Kang (2016), and
their criteria labelled ‘SAE-S’ and ‘DWE-C’ are simple rescalings of
criteria in the ‘Compare T to R’ column of Table 1.
Second, the DWE criterion is preferred over the AE and SAE
criteria for our illustrative data. A criterion for AE would compare
the difference in means between the T and R (or C) groups to a
ﬁxed, externally deﬁned, value. For example, symmetric limit
values, e.g. ln (0.8) and ln (1.25), can be written as a single limit, in
this case ½lnð1:25Þ2. However, such external ﬁxed values are often
not available. Alternatively, the SAE criterion compares the squared
difference to twice the variance s2R. A common choice for an SAE
equivalence limit is z20:975, based on the reasoning that 95% of the
reference means ðmR þ RiÞ will lie in the interval mR±z0:975sR (van
der Voet et al., 2011; Vahl and Kang, 2016), and therefore most of
the differences between two reference means will fall in the in-
terval ±
ﬃﬃﬃ
2
p
z0:975sR. However, a SAE criterion based on s2R runs into
problems when the variance component s2R is small such that es-
timates of this component become zero or very small. For theTable 1
Six equivalence criteria for comparing a Test (T) type to either a population of Reference (
criterion used in this paper.
Criterion
Average equivalence (AE)
Scaled average equivalence (SAE)
Distribution-wise equivalence (DWE)
i, i1 and i2 represent reference feeds in the historic studyexperimental situation considered in this paper (animal feeding
studies) this occurs quite often.
The distribution-wise equivalence (DWE) criterion avoids the
problems mentioned for AE and SAE. When comparing T to C it has
the form, with i1 and i2 representing two reference feeds in the
historic studies:
q ¼
E

yTjk  yCjk
2
E

yi1jk1  yi2jk2
2 ¼ ðmT  mCÞ
2 þ 2s2F
2s2R þ 2s2E
¼ D
2 þ 2s2F
2s2R þ 2s2E
(2)
The DWE criterion considers the two populations of measure-
ments on the experimental units in their entirety, not just the mean
parameters mT and mC . The numerator of q is the expectation of the
squared difference between a unit with the Test feed and a unit
with the Control feed in the current study. This is compared to the
denominator which is the expectation of the squared difference
between a unit with a reference feed and a unit with another
reference feed both in the same (historical) study. Large values of q
may indicate lack of equivalence. Note that the additions þ 2s2F in
the numerator and þ 2s2E in the denominator are the only differ-
ences between the DWE and the SAE criterion. The reasons to
prefer DWE over SAE for data similar to our example are further
discussed in the Discussion section.2.4. Interval estimation using generalized ﬁducial inference
An estimate of q is readily obtained by plugging in the estimates
deﬁned in the previous paragraphs for the parameters D; s2F ; s
2
R
and s2E . These estimates are based on the summary statistics D and
SSF for the current study and SSRjS and SSE for the historic studies.
Based on these summary statistics Y ¼ ðD; SSF ; SSRjS; SSEÞ conﬁ-
dence limits for q can be obtained using Generalized Fiducial
Inference (GFI), a theory that has been developed recently on the
basis of Fisher's ﬁducial argument (see e.g. the review in Hannig
et al., 2016). The general idea of GFI is that a Generalized Fiducial
Distribution (GFD) for the unknown parameter, here q, is con-
structed by inverting the data-generating equation. The data-
generating equation is the model (1) extended with the calcula-
tions leading to the summary statistics Y . In a more general nota-
tion it can be speciﬁed as Y ¼ GðU; xÞ, for data Y , a deterministic
function Gð$; $Þ, ﬁxed but unknown parameters x and random
componentsU with completely known distributions. If it is possible
to invert the equation to x ¼ Q ðU;YÞ , whereQ ð$; $Þ are Generalized
Pivotal Quantities (GPQs), then simulating a large number (in this
paper 10 000) of realizations for the random components U pro-
duces an empirical distribution representing the GFD for the un-
known parameters x. Conﬁdence limits can be obtained as
empirical percentiles of the GFD.
As a simple example, the data generating equation for the sums
of squares SSF can be written as SSF ¼ s2F UF where UF is a random
value from a chi-squared distribution: UF  c2dfF . Inverting thisR) types or a single Control (C) type. The entry for DWE comparing T and C (q) is the
Compare T to R Compare T to C
ðmT  mRÞ2 ðmT  mC Þ2
ðmTmRÞ2
EðRi1Ri2 Þ
2 ¼ ðmTmRÞ
2
2s2R
ðmTmC Þ2
EðRi1Ri2 Þ
2 ¼ ðmTmC Þ
2
2s2R
EðyTjkyijkÞ2
Eðyi1 jk1yi2 jk2 Þ
2 ¼
¼ ðmTmRÞ
2þs2Rþs2Eþs2F
2s2Rþ2s2E
q ¼ EðyTjkyCjk Þ
2
Eðyi1 jk1yi2 jk2 Þ
2 ¼
¼ ðmTmC Þ
2þ2s2F
2s2Rþ2s2E
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parameter s2F . Given an observed SSF , GPQðs2F Þ can be used to derive
a conﬁdence interval for the parameter s2F . In this simple example
this can be done exactly by employing percentiles of the c2dfF dis-
tribution, giving the classical conﬁdence interval for s2F . In a more
general approach, multiple simulations from the appropriate dis-
tribution, in this case c2dfF , can be employed to generate the
Generalized Fiducial Distribution of the unknown parameter s2F .
Finally, 2.5th and 97.5th percentiles of the simulated GFD then give
numerical estimates of the limits of a 95% two-sided conﬁdence
interval.
In the previous paragraph it was shown that the data can be
summarized bymeans of the independent statisticsD; SSF ; SSRjS and
SSE . These can be used in the following way to provide GPQs for the
parameters D; s2F ; s
2
R and s
2
E , using inversion of the data generating
equations given in the previous paragraphs, and deﬁning
Z  Nð0;1Þ, UE  c2dfE , UF  c2dfF , URjS  c2dfRjS :
GPQ

s2F

¼ SSF=UF (3a)
GPQðDÞ ¼ Dþ a Z
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
GPQ

s2F
q
(3b)
GPQ

s2E

¼ SSE=UE (3c)
GPQ

s2R

¼ max
h
0;

SSRjS
.
URjS  GPQ

s2E
.
neff
i
(3d)
The maximisation in (3d) prevents negative estimates of s2R,
which is a commonly used strategy in estimating variance com-
ponents. Note that percentiles of the simulated distribution GPQðDÞ
are just numerical approximations of the usual t-distribution based
conﬁdence limits for D (see e.g. Example 1 in Hannig et al., 2016).
The GPQ for q in equation (2) is then given by replacing parameters
by their respective GPQ's.
GPQðqÞ ¼ ½GPQðDÞ
2 þ 2GPQs2F
2GPQ

s2R
 þ 2GPQs2E (4)
So, conditional on the observed summary statistics D; SSF ; SSRjS
and SSE , equation (4) can be used to simulate a large number of
values giving the generalized ﬁducial distribution of q.
Large values of qmay indicate lack of equivalence, therefore the
100ð1 aÞ% percentile of the GFD deﬁned by (4),
qupp ¼ P100ð1aÞðGPQðqÞÞ, serves as an upper conﬁdence limit for
the magnitude of D (whether positive or negative) translated to the
q scale.2.5. Distribution-wise equivalence test at the q scale
Distribution-wise equivalence testing requires speciﬁcation of a
‘safe’ case which forms the basis for equivalence. To set an equiv-
alence limit at the chosen q scale, we introduce a ‘safe’ case where
there is no difference between T and C (i.e. D ¼ 0) and therefore
values of q are relatively low. For any dataset derived under this no-
difference hypothesis, we deﬁne q0upp as an upper 100ð1 aÞ%
conﬁdence limit for q related to large values of D (whether positive
or negative). Our requirement is that for simulations from the ‘safe’
case, this upper conﬁdence limit will remain below the equivalence
limit (and therefore indicate equivalence) with a pre-set power
1 b. In other words, the equivalence limit will be set as the
100ð1 bÞ% percentile of simulated upper conﬁdence limits.
The ‘safe’ case should not depend on any of the current or his-
torical data, but it should only depend on the design parameters ofthe historical studies. We deﬁne a simpliﬁed ‘safe’ case bymaking a
number of assumptions:
a) There is no difference between the test feed T and control
feed C in the current study, or D ¼ 0 (this corresponds to the
idea of a power analysis for the equivalence test);
b) There is no variability between the reference feeds in the
historical studies, or s2R ¼ 0;
c) The residual variance in the historic and current studies are
identical, or s2F ¼ s2E;
d) The regulatorwill set a minimum sample size n0 for the Tand
C groups to be compared. The idea is that the current
experiment should not be allowed to be too small, which
would lead to unacceptable wide equivalence bands. A value
for n0 may be inspired by external guidance or by values in
the historical data (summarized by the effective sample size
neff ). In principle, n0 will be used to deﬁne the structure of
the current study when calculating the equivalence limit, i.e.
a0 ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2=n0
p
and df0 ¼ 2n0  2.
Using a superscript ‘0’ todenote that thedistributions arederived
under these additional assumptions, the distributions of the four
summary statistics are then given by D0  Nð0; a20s2EÞ,
SS0F  s2E c2df0 , SS0E  s2E c2dfE , and SS0RjS  s2E c2dfRjS . All four distri-
butions have the common variance parameter s2E which will cancel
out in equation (4), andwithout loss of generality we can set s2E ¼ 1.
The four distributions thus do not depend on any parameter; they
only depend on the design of the historical studies, through the
various sample sizes and degrees of freedom, and the regulatory n0.
A simulation approach is now used to ﬁnd out which values of the
DWE criterion q can be expected in this simpliﬁed situation:
1) Simulate the data summary statistics D0; SS0F ; SS
0
E and SS
0
R ac-
cording to the distributions given above, with s2E ¼ 1;
2) Use equation (4) to simulate the GFD0 of q0 for this simulated
dataset using a large number of samples (10 000 in this paper);
3) Summarize the simulated distribution of q0 by means of the
100ð1 aÞ percentile q0upp ¼ P100ð1aÞðGPQ0q Þ of GFD0;
4) Repeat steps 1e3 many times (10 000 in this paper) to obtain
the distribution, say G0a, of q
0
upp under the additional
assumptions;
5) Set the equivalence limit q0 to the 100ð1 bÞ percentile of the
distribution G0a: q0 ¼ P100ð1bÞðq0uppÞ.
Under these assumptions we would like to reject the null hy-
pothesis of no equivalence with a large probability, say 1 b. The
probability 1 b is the power of the equivalence test in the
simpliﬁed situation. Note that q0 only depends on the design values
of the historical studies and on three regulatory values, n0, a and b.
Using the equivalence limit q0 as calculated above, the equiva-
lence test can be carried out for a dataset by calculating the
generalized ﬁducial distribution given by equation (4) for the
observed summary statistics of the historical and current data.
Employing the 100ð1 aÞ percentile qupp of this distribution, the
null hypothesis of no equivalence will be rejected when qupp < q0.2.6. Distribution-wise equivalence test at the equivalence limit
scaled difference (ELSD) scale
The scale of the DWE criterion q is not easily understood. It is
therefore preferable to re-express results on a better recognizable
scale. Firstweexpress resultson themore familiardifference (D) scale
between the test Tand the controlC.Note that for the illustrativedata,
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ratios on the original scale. Secondly, for a full integration of un-
certainties we perform an additional scaling to what we call the
equivalence limit scaled difference (ELSD) scale. As the name
indicates, þ1 and 1 represent the equivalence limits on this scale.
First, on the D scale, the classical conﬁdence interval can be
obtained, either using a parametric calculation or using percentage
points of GPQðDÞ. We now derive how the equivalence limit q0
translates to the D scale. Deﬁne A ¼ 1=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2GPQðs2F Þ
q
and
B ¼ ½GPQðs2RÞ þ GPQðs2EÞ=GPQðs2F Þ then
GPQðqÞ ¼ ½GPQðDÞ
2 þ 2GPQs2F
2GPQ

s2R
 þ 2GPQs2E ¼
½A$GPQðDÞ2 þ 1
B
(5)
For the purpose of deriving symmetric limits on the D scale, the
equivalence limit q0 therefore corresponds to equivalence limits
D0;low;D0;upp with distributions which are found by inverting
equation (5):
ELlow ; ELupp ¼ GPQ

D0;low

;GPQ

D0;upp
 ¼ ± ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðBq0  1Þq

A
provided that Bq0  1>0. Note that A and B are transformed GFDs,
and therefore the equivalence limits on the D scale are also GFDs.
Also note that the equivalence limits D0;low;D0;upp are symmetric
around zero. The medians of the two GFDs can be used as point
estimates, and using 100a=2 and 100ð1 a=2Þ percentile points,
both GFDs can be represented by a conﬁdence interval. We now
have obtained three conﬁdence intervals all based on a GFD: for D,8<
:

ELSD100a=2 ; ELSDlim

if abs

ELSD100a=2

< abs

ELSD100ð1a=2Þ


 ELSDlim ; ELSD100ð1a=2Þ

if abs

ELSD100a=2

 abs

ELSD100ð1a=2Þ
for D0;low and for D0;upp , respectively. It is not clear how to compare
the interval for D with the intervals for the equivalence limits.
Obviously, although the D scale has the advantage of familiarity, it is
not the appropriate scale for a direct representation of the equiv-
alence test.
Therefore, to obtain a scale where equivalence can be repre-
sented directly, we apply a further scaling using the (positive) up-
per equivalence limit. Deﬁne
GPQðELSDÞ ¼ GPQ ðDÞ
GPQ

D0;upp

where ELSD is short for Equivalence Limit Scaled Difference. Now in
this new measure all uncertainties are integrated into one distri-
bution, and the equivalence condition is met when an appropriate
conﬁdence interval derived from GPQðELSDÞ lies completely within
the interval (1,1). We now describe how to construct this conﬁ-
dence interval.
If Bq0  1  0, the corresponding estimates of D0;low;D0;upp are
set both to zero, and it is clear that equivalence cannot be estab-
lished. In order to have a visual indication on the ELSD scale, and
also to deﬁne a distribution of GPQðELSDÞ from which empirical
conﬁdence limits can be calculated, we set GPQðELSDÞ in those
cases to a large negative or positive value, e.g. BIG ¼ 2, with sign
equal to that of GPQðDÞ. The full deﬁnition of GPQðELSDÞ thusbecomes
8>><
>>:
GPQðELSDÞ ¼ GPQ ðDÞ
GPQ

D0;upp
 if Bq0  1>0
GPQðELSDÞ ¼ BIG if Bq0  1  0 and GPQðDÞ<0
GPQðELSDÞ ¼ þBIG if Bq0  1  0 and GPQðDÞ  0
The one-sided test using GPQðqÞ can make no distinction be-
tween positive and negative differences. One-sided intervals on the
q scale therefore correspond to two-sided intervals on the ELSD
scale with lower and upper conﬁdence limits which are perforce
symmetric around 0. By a simple search algorithm we therefore
identify a limit ELSDlim such that
P½GPQðELSDÞ<  ELSDlim þ P½GPQðELSDÞ> ELSDlim ¼ a.
The ELSD scale can also be used for the difference test. Since
GPQðDÞ deﬁnes the classical conﬁdence interval for the difference
D, and the sign of GPQðELSDÞ is always equal to that of GPQðDÞ, it
follows that the classical difference test can be performed by
checking whether the value zero is included in the conﬁdence in-
terval given by the 100a=2 and 100ð1 a=2Þ percentile points
ELSD100a=2 and ELSD100ð1a=2Þ of GPQðELSDÞ. There are thus two
relevant intervals on the ELSD scale: the symmetric interval around
zero for the equivalence test and the interval which corresponds to
the classical difference test. For visualisation of both, we propose an
interval with the most appropriate upper and lower limit, such that
both the difference and equivalence test can be performed by this
single interval. Depending on which of the difference test percen-
tiles is closest to zero, we propose to plot intervals with limits
ðELSDlow; ELSDuppÞ:These intervals, while covering between 100ð1 3a=2Þ and
100ð1 aÞ % of the distribution, can then be used for equivalence
and difference testing. The hypothesis of no difference is rejected in
case the interval does not contain zero, while the non-equivalence
hypothesis is rejected when the interval fully lies inside the interval
(1,1).2.7. Simpliﬁed model assuming s2R ¼ 0
In animal feeding studies there is often little evidence of vari-
ation between reference feeding groups. If the assumption s2R ¼ 0 is
made from the beginning, the statistical model (1) simpliﬁes to
yijk ¼
8<
:
mR þ Sj þ ERjk
mT þ FTk
mC þ FCk
i ¼ R
i ¼ T
i ¼ C
j ¼ 1…nS k ¼ 1…nRj
k ¼ 1…nT
k ¼ 1…nC
(6)
The DWE equivalence criterion (2) reduces to
q ¼ D
2 þ 2s2F
2s2E
(7)
The GPQ calculations described in the previous sections can be
easily modiﬁed for this simpliﬁed model by omitting all terms
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2.8. Power analysis
For a power analysis 1000 datasets were simulated following
the design of the A, B and C studies for the historical data, with 8
replications in studies A and B and 5 replication is study C, and a
simple two-group comparison for the current study, with
nT ¼ nC ¼ 8 replications and dfF ¼ 14 degrees of freedom. It was
assumed that these sample sizes were acceptable for regulators
(no ¼ 8), and residual variances s2E and s2F were arbitrarily set equal
to 1. The between reference variance s2R was set to 0, 0.25 and 1 in
different simulations. Moreover the effect of a larger replication in
the current study was investigated using values of 16, 32, 64 and
128 for nT and nC . In a third set of simulations the degrees of
freedom in the current study was varied between dfF ¼ 14 (corre-
sponding with two groups of 8) and 200 (corresponding with a
current study where many additional feed groups would provide
additional degrees of freedom to estimate the residual variation).
The number of datasets used for calculation of q0 was 10 000 and
the number of GPQ samples was also set to 10 000. The level of
signiﬁcance a was set at 5% and the probability for an equivalence
outcome in the simpliﬁed case ð1 bÞ was set at 95%.
Fig. 1 shows the simulated power against the true effect size
expressed as D=sE . The probability for an equivalence outcome in
the simpliﬁed case, here set at 1 b ¼ 0:95, is indeed attained in
the simpliﬁed situation where D ¼ 0 and s2R ¼ 0. The power de-
creases for increasing true effect sizes. With 8 replications (Fig. 1a)
feeds with a true difference of one standard deviation are still
judged equivalent in 80% of the cases. True variability between
reference feeds (s2R ¼ 0:25 or 1) increases the power, and allows
feeds with larger true differences to be considered equivalent. With
more replications in the current study (Fig. 1b) the power curves
start at higher power and are steeper. With more residual degrees
of freedom in the current study (Fig. 1c) the power curves also start
at higher values, but the differences are smaller in comparison to
panel (b). Finally, note that the true effect size with power equal to
0.05 in panels (b) and (c) appears to be largely independent from
the replication in the current study.
3. Results
As an illustration of the proposed methodology for equivalenceFig. 1. Power of equivalence test in simulations (1000 runs) vs. a background in historical stu
in A and B, 5 replicates in C). Power is shown as a function of the true effect size between
reference foods (sR=sE ¼ 0;0:5;1), nT ¼ nC ¼ 8 replications; (b) results for larger sample
results when using additional groups to have more degrees of freedom in the current studtesting, the observed differences between Test (GM at 33%) and
Control fed male or female rats in study D or E of the Grace project
were analysed against the background of the data for the Reference
and Control (all non-GM) male rats in studies A, B and C. The
method has been applied both with and without the identiﬁed
outliers, and with different values of the regulatory sample size, i.e.
n0 ¼ 5 or 8, corresponding to the typical sample sizes in studies D/E
and A/B, respectively. We assumed regulatory error rates a and b
both equal to 5%. All results are presented graphically in
Supplement 3. In this section we just show one example to illus-
trate the general points.
The summary statistics for the male rats of study D, after
excluding 12 outliers (see Supplement 1), are given in Table 2
where, for a better interpretability, the sums of squares are recal-
culated as standard deviations (s ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SS=df
p
). For the historical data,
the variation between Reference groups sR (estimated from 4 de-
grees of freedom) is always smaller than the variation within
groups sE , and for 20 out of 41 variables it is estimated as zero or
near zero. For BodyWeight and growthR the effective sample size is
larger because these variables are available for 10, rather than 5,
cages in study C. Relative organ weights were only obtained from
historical studies A and B, therefore the effective replication is
smaller. Furthermore slight variations in degrees of freedom for
error dfE and effective replication neff are due to exclusion of out-
liers. In the last two columns of Table 2 we compare estimates of
the standard deviations related to the denominator of the DWE
criterion q, i.e.
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2R þ s2E
q
for model (1) and sE for model (6). It can be
noted that
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2R þ s2E
q
is only slightly larger than sE , with a maximum
change of less than 5% (for TAG).
In a ﬁrst example, we have assumed that the sample sizes in the
historical studies (characterised by neff between 7.7 and 10.5)
roughly represent regulatory needs, and purely for illustration the
regulatory minimum sample size was set to n0 ¼ 8 (cages). It must
be noted that in study D the sample sizes were smaller, nT ¼ nC ¼ 5,
so that a power of 0.95 will not be reached in the simpliﬁed
situation.
In Fig. 2 the observed differences are expressed as ratios of Test
vs. Control, i.e. differences at a logarithmic scale. The black line
segments in Fig. 2 are just the GFD versions of the ordinary 95%
conﬁdence intervals for the differences at the log scale, and their
intersection with the vertical line at ratio ¼ 1 indicates non-dies with similar design as that of most variables in the A, B and C studies (8 replicates
T and C (expressed in SD). (a) results for three values of the true variation between
sizes in the current study, nT ¼ nC ¼ 8; 16;32;64;128 replications, for sR=sE ¼ 0; (c)
y, df F ¼ 14;35;200, for nT ¼ nC ¼ 8 replications and sR=sE ¼ 0.
Table 2
Summary statistics Study D against background from studies A-C. Male rats, outliers excluded. D ¼ difference Test (GM, 33%) and Control in current study, sF is current-study
within-group standard deviation with df F degrees of freedom, sE and sR are historical-study within- and between-group standard deviations with df E and df R degrees of
freedom, neff is effective sample size in the historical studies. All statistics are calculated under model (1), except sE in the last column, which is calculated under model (6).
study D (GM vs. Control) A, B, C (non-GM)
variable D sF df F sE df E sR df R neff
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2R þ s2E
q
sE (M6)
BodyWeight 0.012 0.052 8 0.056 61 0.000 4 10.5 0.056 0.055
growthR 0.000 0.019 8 0.019 60 0.000 4 10.3 0.019 0.019
Kidney 0.041 0.054 8 0.054 42 0.000 4 8.0 0.054 0.053
Spleen 0.070 0.080 8 0.086 42 0.000 4 8.0 0.086 0.086
Liver 0.028 0.049 8 0.051 40 0.006 4 7.7 0.051 0.051
AdrenGl 0.026 0.085 8 0.120 42 0.000 4 8.0 0.120 0.119
Lung 0.041 0.064 8 0.077 42 0.035 4 8.0 0.085 0.083
Heart 0.007 0.035 8 0.051 42 0.013 4 8.0 0.052 0.052
Thymus 0.083 0.087 8 0.184 42 0.004 4 8.0 0.184 0.184
Pancreas 0.063 0.133 8 0.145 41 0.056 4 7.8 0.156 0.153
Testis 0.057 0.074 8 0.076 42 0.000 4 8.0 0.076 0.075
Epididymis 0.041 0.104 8 0.081 42 0.000 4 8.0 0.081 0.079
Brain 0.016 0.055 8 0.050 42 0.016 4 8.0 0.052 0.052
WBC 0.244 0.154 8 0.220 51 0.089 4 9.2 0.237 0.232
RBC 0.023 0.034 8 0.053 51 0.000 4 9.2 0.053 0.052
HGB 0.011 0.028 8 0.043 50 0.006 4 9.1 0.044 0.043
HCT 0.004 0.023 8 0.051 51 0.000 4 9.2 0.051 0.050
MCV 0.019 0.020 8 0.019 51 0.000 4 9.2 0.019 0.018
MCH 0.033 0.032 8 0.027 50 0.000 4 9.1 0.027 0.026
MCHC 0.015 0.017 8 0.016 50 0.003 4 9.1 0.016 0.016
PLT 0.071 0.111 8 0.270 51 0.000 4 9.2 0.270 0.262
LYMcount 0.228 0.153 8 0.217 51 0.076 4 9.2 0.230 0.225
Lymphocyte 0.058 0.046 8 0.045 51 0.003 4 9.2 0.045 0.045
Neutrophil 0.254 0.153 8 0.166 51 0.000 4 9.2 0.166 0.165
Monocyte 0.065 0.279 8 0.294 51 0.126 4 9.2 0.320 0.312
Eosinophil 0.478 0.380 8 0.457 51 0.164 4 9.2 0.486 0.476
ALP 0.206 0.162 8 0.176 51 0.000 4 9.2 0.176 0.172
ALT 0.045 0.119 8 0.120 49 0.000 4 8.9 0.120 0.119
AST 0.171 0.159 8 0.156 50 0.000 4 9.1 0.156 0.155
Alb 0.023 0.051 8 0.055 50 0.000 4 9.1 0.055 0.054
Glu 0.038 0.090 8 0.146 51 0.038 4 9.2 0.150 0.149
Krea 0.000 0.126 8 0.132 51 0.029 4 9.2 0.135 0.134
TP 0.020 0.041 8 0.040 51 0.000 4 9.2 0.040 0.040
Urea 0.106 0.062 8 0.100 51 0.057 4 9.2 0.116 0.111
CHOL 0.043 0.120 8 0.110 51 0.054 4 9.2 0.123 0.119
Ca 0.017 0.016 8 0.064 51 0.012 4 9.2 0.065 0.065
Cl 0.016 0.010 8 0.051 51 0.002 4 9.2 0.051 0.051
K 0.066 0.071 8 0.112 51 0.000 4 9.2 0.112 0.110
Na 0.003 0.013 8 0.056 51 0.000 4 9.2 0.056 0.056
P 0.074 0.072 8 0.101 50 0.029 4 9.1 0.105 0.103
TAG 0.065 0.233 8 0.294 51 0.178 4 9.2 0.343 0.328
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and Urea are seen to be signiﬁcantly smaller in the Test group than
in the Control group, and WBC and LYMcount are signiﬁcantly
greater. The new elements in Fig. 2 are the estimated equivalence
limits ELlow and ELupp together with their 95% conﬁdence bounds.
The variables have been sorted within their category in order of
increasing median equivalence limit. Except for MCH all interval
estimates of the ratio Test/Control (the black lines) are between the
median equivalence limits (the red limits), including those for
Neutrophils and Urea. In several cases, however, the 95% conﬁdence
interval for the ratio and the 95% conﬁdence interval for the
equivalence limit do overlap. The D scale in Fig. 2 cannot be used to
perform an equivalence test. For that purposewe consider the ELSD
scale in Fig. 3 where all uncertainties have been incorporated in the
ELSD statistic. As explained in the Methods section, the conﬁdence
limit closest to 0, which can be used for the two-sided difference
test, excludes 100a=2 percent of the distribution, whereas the other
conﬁdence limit, to be used in the one-sided equivalence test, ex-
cludes between 100a=2 and 100a percent of the distribution. From
Fig. 3 it follows that 36 out of the 41 intervals (78%) are between the
standardised equivalence limits1 andþ1. For 5 of the 41 variables
the experiment with 5 cages per groups is insufﬁcient to produceELSD intervals that are fully in the equivalence range. Note, how-
ever, that all point estimates are still in the interval ±1, so in the
terminology of EFSA (2010a, 2011a,b) equivalence is ‘more likely
than not’.
Just for illustration of themethodwe have also assumed that the
sample size of study Dwas in agreement with regulatory needs, e.g.
the regulatory minimum sample size was set to n0 ¼ 5 (cages).
Fig. 4 shows that in this case all conﬁdence intervals are in the
interval ±1. Note that we are separately testing equivalence for 41
variables without any attempt to correct for the multiplicity,
therefore around 5% of the intervals extending outside the ±1 limits
(around 2 out of 41) can be expectedwithout statistically indicating
a lack of equivalence.
Fig. 4 also shows the effects of including or excluding the
identiﬁed outliers. In this example all 12 outliers occurred in the
historical data (none in the current data), and therefore the result of
excluding outliers is a more narrow equivalence bandwidth and
consequently a somewhat wider ELSD interval. The conclusions of
the equivalence tests are however not changed.
Finally, Fig. 5 compares the ELSD intervals derived under the
standard model (1), which includes a term Ri for between-
reference group variation, and the simpliﬁedmodel (6), where s2R ¼
Fig. 2. Conﬁdence intervals Test vs. Control in study D, Males, compared to the non-GM background in studies ABC (12 outliers excluded), requiring n0 ¼ 8 as the minimum number
of cages per group. Shown are the observed ratios corresponding to differences D on the log scale, with 95% conﬁdence limits (black symbols and line segments), the median
equivalence limits EL (red bars delimiting a green equivalence band width), and the 2.5% and 97.5% conﬁdence limits for EL (blue bars). (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
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tervals were very small.
4. Discussion
A new method for safety assessment of innovative products has
been proposed and was applied to existing data. The advantage of
the proposed method is that it employs available data from previ-
ous studies to characterise the variation of observations on
different reference groups that are assumed to be safe. Theequivalence limits are derived in such a way that an experiment
with two groups with no difference would give a conﬁdence in-
terval for the group difference that would lie in between the
equivalence limits with a predetermined probability. In this respect
the proposed approach falls under the concept of tolerance in-
tervals which have similar properties (Kang and Vahl, 2014; Hong
et al., 2014).
Statistical testing is an asymmetric procedure, both for differ-
ence and for equivalence testing. Note that in our procedure we
attempt to demonstrate equivalence by rejecting a hypothesis of
Fig. 3. Equivalence testing Test vs. Control in study D, Males, compared to the non-GM background in studies ABC (12 outliers excluded), requiring n0 ¼ 8 as the minimum number
of cages per group. Median ELSD with 92.5e95% conﬁdence interval (see text).
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non-equivalence. Further, non-equivalence of a Test group versus a
Control groups does not imply a verdict about safety, but only about
an observed difference which is larger than has been seen previ-
ously for the reference groups. Safety assessment is always more
than just a statistical equivalence test, and needs the interpretation
of the results by experts.
In equivalence testing for drugs, expert-based ﬁxed values are
commonly used for equivalence limits (FDA, 2003; EMA, 2010).
When experts are able to set such limits, this is a reasonable pro-
cedure. For cases where experts have difﬁculties to translate their
expertise to numerical values even when historical datasets onreference groups are available, the proposed procedure may be
helpful as an alternative.
In the context of animal feeding studies the use of standardised
effect size (SES) has been suggested by EFSA (2011b). SES is the
observed difference between group means divided by one standard
deviation between experimental units. The reasoning of EFSA was:
‘If experience from previous toxicity tests shows that an effect size of,
say, one SD or less is of little toxicological relevance then this can be
used to determine sample size in new situations’. In other words, EFSA
sketches an example where one SD is considered an appropriate
equivalence limit. In the absence of other externally provided
equivalence limits SES has been used in previous analyses of the
Fig. 4. Equivalence testing Test vs. Control in study D, Males, compared to the non-GM background in studies ABC, requiring n0 ¼ 5 as the minimum number of cages per group.
Median ELSD with 92.5e95% conﬁdence interval (see text). Results shown before (upper, black) and after (lower, red) excluding 12 outliers from the historical data (two outliers for
Liver and ALT, one outlier for growthR, Pancreas, HGB, MCH, MCHC, AST, Alb and P). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the
web version of this article.)
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equivalence testing is to be preferred over difference testing in the
safety assessment of GM plants (Schmidt et al., 2015a, b, 2016;
2017; Zeljenkova et al., 2014; 2016). In this paper we have pro-
posed an alternative to the purely hypothetical assumption of EFSA
that one SD would be a reasonable equivalence limit, by using
historical data to specify equivalence limits.
We have assumed potentially different residual variances for the
historical and the current study (s2E and s
2
F , respectively). If the
variances would in fact be the same, there would be a beneﬁt ofpooling the variance estimates for the historical and current data.
However, in regulatory equivalence testing, there is a potential
danger in using the variances from the current experiment (typi-
cally under control of the applicant) in a role where a larger vari-
ance effectively may widen the equivalence region [ELlow, ELupp] of
the type as shown in Fig. 2. This could lead to a situationwhere lack
of precision in the current experiment would lead to easier
acceptance of equivalence, which is undesirable. For this reason we
chose the model such that the historical data (reviewed and
accepted by the regulators) set a standard for variances and
Fig. 5. Equivalence testing Test vs. Control in study D, Males, compared to the non-GM background in studies ABC (12 outliers excluded), requiring n0 ¼ 8 as the minimum number
of cages per group. Results for the standard model (1) (upper, black) and simpliﬁed model (6) with s2R ¼ 0 (lower, red). Median ELSD with 92.5e95% conﬁdence interval (see text).
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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assuming a single residual variance in model (1) or (6) which uses
two GPQ estimates in equation (4): a pooled estimate in the
numerator and an estimate based on only the historical data in the
denominator. However, in that case, a researcher who conducts a
current experiment with improved precision would not gain the
full beneﬁt of this improvement. The proposed approach can be
adapted to the needs of regulators in speciﬁc cases regarding the
allowed role of data from the current study for estimating precision
and also for estimating between-reference variation if more refer-
ences are available.We have argued that DWE is preferable over SAE when the
between feed variance component (s2RÞ is zero or small. Application
of SAE is clearly impossible when s2R is zero, but in theory it could
still be applied for any positive estimate. However, in our example
the point estimates sR were mostly below 0.1, and a difference of
less than one standard deviation corresponds to a ratio lower than
expð0:1Þ  1 ¼ 10% at the original scale (only three estimates
were higher: 0.178 for TAG, 0.164 for Eosinophils and 0.126 for
Monocytes). Commonly, but not always, equivalence testing con-
siders wider limits than 10%, and in such cases using estimates of
variation with lower values seems contrary to the intentions.
H. van der Voet et al. / Food and Chemical Toxicology 109 (2017) 472e485484Perhaps more importantly, in our example the between feed vari-
ance component (s2RÞ could only be estimated with four degrees of
freedom. As a consequence the estimates sR in Table 2 are very
imprecise. For example, 95% conﬁdence intervals for sR using
equation (3d) are 0.000e0.037 for BodyWeight (point estimate
0.000), and 0.067e0.563 for TAG (point estimate 0.178). In using
SAE for equivalence testing, employing 0:5 GPQ2ðDÞ=GPQ2ðs2RÞ in
analogy with the proposed approach for DWE, we would use the
95th percentile of the distribution of this ratio. This only makes
sense when at least 95% of the GPQ values for s2R are positive, but
this was only the case for the ﬁve variables TAG (99.6%), Urea
(99.3%), CHOL (98.3%), Monocyte (96.0%) and Lung (95.6%). There-
fore, application of SAE is not an option for most variables in our
case study. However, for four of the ﬁve remaining variables, the
highly uncertain s2R estimate still caused the upper 95% limit of the
SAE criterion to attain much higher values than the SAE criterion
z20:975 ¼ 3:84. The 95% upper limits were 3.15 (TAG), 11.07 (Urea),
14.60 (CHOL), 46.91 (Monocyte) and 55.85 (Lung), respectively, so
that only for TAG equivalencewould be shown by SAE. Note that the
uncertainty of s2R plays a smaller role in the DWE criterion, because
s2E is added to the denominator which, for the current data set, is
typically a larger value with less uncertainty.
When estimates of s2R are small, another option is to omit s
2
R
from the DWE model altogether. This is model (6), and for the case
study in this paper the results were very similar to the results of
model (1). Experience with more data sets would be needed to
justify a general preference for making the extra assumption
s2R ¼ 0.
Estimating historical variation between feeds with only four
degrees of freedom is not ideal, and is due to the lack of a long
history of comparable data for non-GM foods in the test facility. The
proposed method using model (1) will be most useful in an infra-
structure, for example a routine testing laboratory, where a longer
series of historical studies, each involving at least two non-GM
feeding groups, are available for the characterisation of reference
variation. A requirement of at least two reference groups per
feeding study would be new, but is helpful for establishing the
appropriate background data for equivalence testing using model
(1).
It should be stressed that the analysis in this paper is just an
illustration of methodology, and not a real safety assessment. As a
ﬁrst point, a full safety assessment would require case-by-case
interaction with regulators and risk assessors regarding the
choice of variables that is needed to cover the spectrum of possible
unintended effects. Such interaction could suggest a sufﬁcient set of
variables based on potential and plausible pathways to harm. A
second point would be a choice between external, expert-set
equivalence limits and equivalence procedures based on historical
data. In the latter case, a third point to be decided by regulators
would be the speciﬁcation of experimental effort, for example in
the form of a ﬁxed minimum sample size n0, e.g. conforming OECD
guidance, or by specifying that a current experiment would need to
have at least the same sample size as has been used in historical
experiments.
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